...
首页> 外文期刊>Antimicrobial agents and chemotherapy. >Heteroresistance to Itraconazole Alters the Morphology and Increases the Virulence of Cryptococcus gattii
【24h】

Heteroresistance to Itraconazole Alters the Morphology and Increases the Virulence of Cryptococcus gattii

机译:对伊曲康唑的异抗性会改变加泰隐球菌的形态并增加其毒力

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Cryptococcus gattii is the main etiological agent of cryptococcosis in immunocompetent individuals. The triazole drug itraconazole is one of the antifungals used to treat patients with cryptococcosis. Heteroresistance is an adaptive mechanism to counteract the stress of increasing drug concentrations, and it can enhance the ability of a microorganism to survive under antifungal pressure. In this study, we evaluated the ability of 11 C. gattii strains to develop itraconazole heteroresistance. Heteroresistant clones were analyzed for drug susceptibility, alterations in cell diameter, capsule properties, and virulence in a murine model. Heteroresistance to itraconazole was intrinsic in all of the strains analyzed, reduced both the capsule size and the cell diameter, induced molecular heterogeneity at the chromosomal level, changed the negatively charged cells, reduced ergosterol content, and improved the antioxidant system. A positive correlation between surface/volume ratio of original cells and the level of heteroresistance to itraconazole (LHI) was observed in addition to a negative correlation between capsule size of heteroresistant clones and LHI. Moreover, heteroresistance to itraconazole increased the engulfment of C. gattii by macrophages and augmented fungal proliferation inside these cells, which probably accounted for the reduced survival of the mice infected with the heteroresistant clones and the higher fungal burden in lungs and brain. Our results indicate that heteroresistance to itraconazole is intrinsic and increases the virulence of C. gattii. This phenomenon may represent an additional mechanism that contributes to relapses of cryptococcosis in patients during itraconazole therapy.
机译:加蒂隐球菌是免疫活性个体中隐球菌病的主要病原体。三唑药物伊曲康唑是用于治疗隐球菌病患者的抗真菌药之一。异质电阻是一种抵抗药物浓度增加的压力的适应性机制,它可以增强微生物在抗真菌压力下生存的能力。在这项研究中,我们评估了11 C. gattii菌株发展伊曲康唑异抗性的能力。在鼠模型中,分析了具有抗药性的克隆的药敏性,细胞直径的变化,胶囊性质和毒力。对伊曲康唑的异抗性在所有分析菌株中都是固有的,降低了胶囊的大小和细胞直径,在染色体水平上诱导了分子异质性,改变了带负电荷的细胞,降低了麦角固醇含量,并改善了抗氧化系统。除异源抗性克隆的胶囊大小与LHI之间呈负相关外,还观察到原始细胞的表面/体积比与对伊曲康唑的异抗性水平之间呈正相关。此外,对伊曲康唑的异抗性增加了巨噬细胞对加蒂梭菌的吞噬并增加了这些细胞内部的真菌增殖,这可能解释了感染了异抗性克隆的小鼠的存活率降低以及肺和脑中较高的真菌负担。我们的结果表明,对伊曲康唑的异抗性是内在的,会增加加蒂梭菌的毒力。这种现象可能代表了导致伊曲康唑治疗期间患者隐球菌病复发的另一种机制。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号